Activating fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies

Journal of Experimental Medicine

Volumn 210, Issue 9, 2013, Pages 1685-1693

  Bulliard, Yannick ^a   Jolicoeur, Rose ^a   Windman, Maurice ^a   Rue, Sarah M ^b   Ettenberg, Seth ^a   Knee, Deborah A ^b   Wilson, Nicholas S ^a   Dranoff, Glenn ^c,d   Brogdon, Jennifer L ^a  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^b Genomic Institute of the Novetis Foundation   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; FC RECEPTOR; FC RECEPTOR IIB; GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR RECEPTOR; RECEPTOR ANTIBODY; RECEPTOR ANTIBODY DTA1; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL LOSS; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG TARGETING; IMMUNOREGULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; T CELL DEPLETION; T LYMPHOCYTE ACTIVATION; TUMOR ASSOCIATED LEUKOCYTE;

ANIMALS; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC AGENTS; CTLA-4 ANTIGEN; FEMALE; GLUCOCORTICOID-INDUCED TNFR-RELATED PROTEIN; IMMUNOLOGIC FACTORS; LYMPHOCYTE DEPLETION; MICE; MICE, INBRED BALB C; NEOPLASMS; RECEPTORS, IGG; T-LYMPHOCYTES, REGULATORY;

EID: 84884229186     PISSN: 00221007     EISSN: 15409538     Source Type: Journal    
DOI: 10.1084/jem.20130573     Document Type: Article

References (33)

1. Albanesi, M., D.A. Mancardi, L.E. Macdonald, B. Iannascoli, L. Zitvogel, A.J. Murphy, M. Daëron, J.H. Leusen, and P. Bruhns. 2012. Cutting edge: FcγRIII (CD16) and FcγRI (CD64) are responsible for antiglycoprotein 75 monoclonal antibody TA99 therapy for experimental metastatic B16 melanoma. J. Immunol. 189:5513-5517. http://dx.doi .org/10.4049/jimmunol.1201511
2. Chao, D.T., X. Ma, O. Li, H. Park, and D. Law. 2009. Functional characterization of N297A, a murine surrogate for low-Fc binding antihuman CD3 antibodies. Immunol. Invest. 38:76-92. http://dx.doi.org/ 10.1080/08820130802608238
3. Chung, K.Y., I. Gore, L. Fong, A. Venook, S.B. Beck, P. Dorazio, P.J. Criscitiello, D.I. Healey, B. Huang, J. Gomez-Navarro, and L.B. Saltz. 2010. Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer. J. Clin. Oncol. 28:3485-3490. http:// dx.doi.org/10.1200/JCO.2010.28.3994
4. Clynes, R.A., T.L. Towers, L.G. Presta, and J.V. Ravetch. 2000. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat. Med. 6:443-446. http://dx.doi.org/10.1038/74704
5. Cohen, A.D., D.A. Schaer, C. Liu, Y. Li, D. Hirschhorn-Cymmerman, S.C. Kim, A. Diab, G. Rizzuto, F. Duan, M.A. Perales, et al. 2010. Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation. PLoS ONE. 5:e10436. http://dx.doi.org/10.1371/journal .pone.0010436
6. Curran, M.A., W. Montalvo, H. Yagita, and J.P. Allison. 2010. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc. Natl. Acad. Sci. USA. 107:4275-4280. http://dx.doi.org/10.1073/pnas.0915174107
7. Hodi, F.S., S.J. O'Day, D.F. McDermott, R.W. Weber, J.A. Sosman, J.B. Haanen, R. Gonzalez, C. Robert, D. Schadendorf, J.C. Hassel, et al. 2010. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363:711-723. http://dx.doi.org/10.1056/ NEJMoa1003466
8. Hogarth, P.M., and G.A. Pietersz. 2012. Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond. Nat. Rev. Drug Discov. 11:311-331. http://dx.doi.org/10.1038/nrd2909
9. Junttila, T.T., K. Parsons, C. Olsson, Y. Lu, Y. Xin, J. Theriault, L. Crocker, O. Pabonan, T. Baginski, G. Meng, et al. 2010. Superior in vivo efficacy of afucosylated trastuzumab in the treatment of HER2-amplified breast cancer. Cancer Res. 70:4481-4489. http://dx.doi.org/10.1158/0008- 5472.CAN-09-3704
10. Kanamaru, F., P. Youngnak, M. Hashiguchi, T. Nishioka, T. Takahashi, S. Sakaguchi, I. Ishikawa, and M. Azuma. 2004. Costimulation via glucocorticoid- induced TNF receptor in both conventional and CD25+ regulatory CD4+ T cells. J. Immunol. 172:7306-7314.
11. Ko, K., S. Yamazaki, K. Nakamura, T. Nishioka, K. Hirota, T. Yamaguchi, J. Shimizu, T. Nomura, T. Chiba, and S. Sakaguchi. 2005. Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells. J. Exp. Med. 202:885-891. http://dx.doi.org/10.1084/jem.20050940
12. Leach, D.R., M.F. Krummel, and J.P. Allison. 1996. Enhancement of antitumor immunity by CTLA-4 blockade. Science. 271:1734-1736. http:// dx.doi.org/10.1126/science.271.5256.1734
13. Lewis, G.D., I. Figari, B. Fendly, W.L. Wong, P. Carter, C. Gorman, and H.M. Shepard. 1993. Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies. Cancer Immunol. Immunother. 37:255-263. http://dx.doi.org/10.1007/BF01518520
14. Li, F., and J.V. Ravetch. 2012. A general requirement for FcγRIIB coengagement of agonistic anti-TNFR antibodies. Cell Cycle. 11:3343- 3344. http://dx.doi.org/10.4161/cc.21842
15. Mellman, I., G. Coukos, and G. Dranoff. 2011. Cancer immunotherapy comes of age. Nature. 480:480-489. http://dx.doi.org/10.1038/nature10673
16. Nimmerjahn, F., and J.V. Ravetch. 2005. Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science. 310:1510- 1512. http://dx.doi.org/10.1126/science.1118948
17. Nimmerjahn, F., and J.V. Ravetch. 2008. Fcgamma receptors as regulators of immune responses. Nat. Rev. Immunol. 8:34-47. http://dx.doi .org/10.1038/nri2206
18. Nimmerjahn, F., and J.V. Ravetch. 2012. Translating basic mechanisms of IgG effector activity into next generation cancer therapies. Cancer Immun. 12:13.
19. Niwa, R., M. Sakurada, Y. Kobayashi, A. Uehara, K. Matsushima, R. Ueda, K. Nakamura, and K. Shitara. 2005. Enhanced natural killer cell binding and activation by low-fucose IgG1 antibody results in potent antibody- dependent cellular cytotoxicity induction at lower antigen density. Clin. Cancer Res. 11:2327-2336. http://dx.doi.org/10.1158/1078-0432. CCR-04-2263
20. Nordstrom, J.L., S. Gorlatov, W. Zhang, Y. Yang, L. Huang, S. Burke, H. Li, V. Ciccarone, T. Zhang, J. Stavenhagen, et al. 2011. Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding properties. Breast Cancer Res. 13:R123. http://dx.doi.org/10.1186/bcr3069
21. Robert, C., L. Thomas, I. Bondarenko, S. O'Day, J.W. M D, C. Garbe, C. Lebbe, J.F. Baurain, A. Testori, J.J. Grob, et al. 2011. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 364:2517-2526. http://dx.doi.org/10.1056/NEJMoa1104621
22. Ronchetti, S., G. Nocentini, R. Bianchini, L.T. Krausz, G. Migliorati, and C. Riccardi. 2007. Glucocorticoid-induced TNFR-related protein lowers the threshold of CD28 costimulation in CD8+ T cells. J. Immunol. 179:5916-5926.
23. Ronchetti, S., G. Nocentini, M.G. Petrillo, and C. Riccardi. 2012. CD8+ T cells: GITR matters. ScientificWorldJournal. 2012:308265. http://dx.doi .org/10.1100/2012/308265
24. Schaer, D.A., J.T. Murphy, and J.D. Wolchok. 2012. Modulation of GITR for cancer immunotherapy. Curr. Opin. Immunol. 24:217-224. http://dx.doi .org/10.1016/j.coi.2011.12.011
25. Sharma, S., A.L. Dominguez, S.Z. Manrique, F. Cavallo, S. Sakaguchi, and J. Lustgarten. 2008. Systemic targeting of CpG-ODN to the tumor microenvironment with anti-neu-CpG hybrid molecule and T regulatory cell depletion induces memory responses in BALB-neuT tolerant mice. Cancer Res. 68:7530-7540. http://dx.doi.org/10.1158/0008- 5472.CAN-08-1635
26. Shields, R.L., A.K. Namenuk, K. Hong, Y.G. Meng, J. Rae, J. Briggs, D. Xie, J. Lai, A. Stadlen, B. Li, et al. 2001. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J. Biol. Chem. 276:6591-6604. http://dx.doi.org/10.1074/ jbc.M009483200
27. Shimizu, J., S. Yamazaki, T. Takahashi, Y. Ishida, and S. Sakaguchi. 2002. Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance. Nat. Immunol. 3:135-142. http://dx.doi .org/10.1038/ni759
28. Smith, P., D.J. DiLillo, S. Bournazos, F. Li, and J.V. Ravetch. 2012. Mouse model recapitulating human Fcγ receptor structural and functional diversity. Proc. Natl. Acad. Sci. USA. 109:6181-6186. http://dx.doi.org/10 .1073/pnas.1203954109
29. Tai, Y.T., H.M. Horton, S.Y. Kong, E. Pong, H. Chen, S. Cemerski, M.J. Bernett, D.H. Nguyen, S. Karki, S.Y. Chu, et al. 2012. Potent in vitro and in vivo activity of an Fc-engineered humanized anti-HM1.24 antibody against multiple myeloma via augmented effector function. Blood. 119:2074-2082. http://dx.doi.org/10.1182/blood-2011- 06-364521
30. Turk, M.J., J.A. Guevara-Patiño, G.A. Rizzuto, M.E. Engelhorn, S. Sakaguchi, and A.N. Houghton. 2004. Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J. Exp. Med. 200:771-782. http://dx.doi.org/10.1084/jem.20041130
31. Weng, W.K., and R. Levy. 2003. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J. Clin. Oncol. 21:3940-3947. http://dx.doi .org/10.1200/JCO.2003.05.013
32. Wilson, N.S., B. Yang, A. Yang, S. Loeser, S. Marsters, D. Lawrence, Y. Li, R. Pitti, K. Totpal, S. Yee, et al. 2011. An Fcγ receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells. Cancer Cell. 19:101-113. http://dx.doi.org/10.1016/j.ccr .2010.11.012
33. Zhou, P., L. L'italien, D. Hodges, and X.M. Schebye. 2007. Pivotal roles of CD4+ effector T cells in mediating agonistic anti-GITR mAb-inducedimmune activation and tumor immunity in CT26 tumors. J. Immunol. 179:7365-7375.